NCT05535764View on ClinicalTrials.gov

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

October 30, 2027

Conditions
Myelofibrosis
Interventions
DRUG

Pegylated interferon alpha2a

PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute at the University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER